Aratana introduced new advance for extended pain relief at IVECCS 2016
At the International Veterinary Emergency and Critical Care Symposium (IVECCS) 2016 in the greater Dallas area last week, Aratana introduced conference attendees to NOCITA® (bupivacaine liposome injectable suspension), a new therapeutic that recently received FDA approval as a local post-operative analgesic for cranial cruciate ligament (CCL) surgery in dogs.
NOCITA is a long-acting local anesthetic that provides up to 72 hours of pain control following CCL surgery in dogs. It works by releasing bupivacaine over time from multivesicular liposomes deposited in the tissue when administered during surgical closure.
Visitors to the Aratana Therapeutics booth at IVECCS were invited to pre-order NOCITA and attend a Saturday breakfast session featuring a presentation by Jessica Wofford, DVM, PhD, Aratana Therapeutics, entitled “Post-Operative Pain in Dogs: New Advances for Extended Pain Relief.”
In her presentation, Dr. Wofford shared pivotal efficacy and safety data for NOCITA, including results from a multi-center, placebo-controlled, randomized and masked field study of 182 client-owned dogs undergoing cranial cruciate ligament stabilization surgery. The study showed NOCITA provided statistically significantly higher success rates for dogs compared to placebo at both primary and secondary endpoints. Results also showed that NOCITA was well-tolerated and adverse reactions, such as discharge from incision, incisional inflammation and vomiting, were infrequent and mild.
Dr. Wofford further explained the previously unmet need for better post-surgical pain management and how NOCITA helps to bridge that gap.
“Local anesthetics can serve as an important component for post-operative pain management, but previously available products had a limited duration of action, making them less useful for pain management in the days following surgery,” said Dr. Wofford. “Given the ability of local anesthetics to completely block pain transmission signals, there has always been a desire for a long-acting local anesthetic. NOCITA now enables veterinarians to provide local analgesia for up to 72 hours following CCL surgery in dogs.”
For a better understanding of how NOCITA works, watch the NOCITA Mechanism of Action video.
You can find the latest information about NOCITA, including the clinical overview, safety and efficacy studies here. IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCI, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.
The Company announced its second quarter 2017 financial results and will host a live conference call on Friday, August 4, 2017 at 8:30 a.m. ET to discuss financial results from the second quarter ended June 30, 2017.